Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Alexza Pharmaceuticals, Inc.

Home Clinical Trial Sponsors and OrganizationsAlexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals, Inc.

ACTIVE

6550 Dumbarton Cir Ste A, Fremont, California, United Stateswww.alexza.comSubsidiary51–100 employeesEstablished: 2001-01-01

Part of GRUPO FERRER INTERNACIONAL SA

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

34

0 active

Approvals

2

Total approvals

Agencies

1

Regulatory bodies

Founded

2001

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

17

50.0%

Phase 2

9

26.5%

Phase 3

2

5.9%

Phase 4

2

5.9%

Trial Status Distribution

Completed

32

94.1%

Suspended

1

2.9%

Terminated

1

2.9%

Clinical Trials

Trials sponsored by this organization (34)

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Sep 20238 participants

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

Feb 2021150 participants

Staccato® Granisetron Multiple Dose PK

Mar 202030 participants

Staccato® Granisetron Single Dose PK

Nov 201936 participants

Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease

Oct 201935 participants

Staccato Apomorphine Single and Multi Dose PK

Nov 201856 participants

Staccato Alprazolam and Photoparoxysmal Response

Jan 20155 participants

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Nov 201410,000 participants

Page 1 of 5

Approvals

Approvals by Agency

FDA

Food and Drug Administration

2

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials34
Approvals2
News

Back to Organizations